LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Screwless Spine Fusion Implant Focus of New Study
Spine

Screwless Spine Fusion Implant Focus of New Study

March 17, 2021 2 min read Premium comments

Advertisement

Screwless Spine Fusion Implant Focus of New Study
ZygoFix’s zLOCK vs. screw and rod / Source: ZygoFix Ltd
Secondary#zygofix#israelinnovationauthority#zlock

An Israel-based study of a novel, screwless spinal fusion implant has just been started by the senior spine surgeon at Rambam Health Care Campus and principal investigator, Dr. Lior Merom. The first clinical case was a laminotomy and facet stabilization using two of the novel implants to achieve relief of back pain due to facet arthritis and spinal nerve compression (foraminal stenosis).

The implant is a miniature screwless implant that is able to delivery spinal stability and fusion by bending and adjusting to specific joint shapes during insertion. The manufacturer, ZygoFix Ltd, which has brand named the new implant ‘zLOCK’, says that it is a least invasive and simplist fusion option that could, potentially, replace complex screw stabilization.

The new clinical study will be used to measure how effective and safe zLOCK is. According to ZygoFix CEO Ofer Levy, “The first patient to undergo the procedure in Israel, was admitted to surgery due to facet degeneration in L4/5 and reported VAS [Visual Analog Score] pain levels of 10 Back, 6 Leg. Today, three weeks post-op, she reports a reduction in VAS to 2 Back, 2 Leg. Placement of the zLOCK took less than 30 minutes (bi-lateral).”

Furthermore, says Levy, “The study in Israel is following the EU pilot study that is ongoing since April 2018. The principal investigator of the study in the EU, Professor Attila Schwarcz stated: ‘zLOCK is a no-risk surgery: the procedure is performed far from the nerve roots, the neurological complication rate is expected to be close to zero.’ The first patients that completed the study (24 months follow up) report an average reduction of 70% in VAS and 62% in ODI [Oswestry Disability Index].”

In Levy’s view, the technology could rethink spinal stability. “We leverage the natural anatomical structure of the spine and insert the zLOCK implant which locks the motion in the joint.”

And, says Levy, it is more simple than traditional pedicle screw based systems. “This customization doesn’t require any effort from the surgeon as it is performed automatically while inserting the implant into the joint.”

The current study, according to Levy, will continue to expand. “Following the opening of the Israel site and starting to recruit patients, we are looking into opening a wider pivotal study in the EU. The Israeli study will include an additional site in Assuta Medical Center and in total with the EU study will enroll 40 patients.”

Concerning future system and tools enhancements, Levy told OTW, “We are enhancing the implant and tools for an easier implantation process, further improvement in primary stability and better visualization of bone growth.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy